[Ip-health] ACT NOW! Urge Johns Hopkins to keep TB innovation accessible for all!

Merith Basey merith at essentialmedicine.org
Fri Aug 21 07:43:07 PDT 2015


Dear advocates,



Join UAEM and our allies in urging Johns Hopkins University (JHU) to
provide a public commitment to the licensing agreement for an innovative TB
drug named Sutezolid developed at the university; and to offer a
non-exclusive license to develop the product as part of a novel,
appropriate and affordable regimen for DR-TB patients.


*Sign and share our petition now
<https://uaem.wufoo.com/forms/z1dxtbgq0ieib3a/>*. In addition, we are
seeking accountability and transparency throughout the process and ask JHU
to make the terms and conditions of the licensing agreement available for
review both before and after it is finalized.



*Sutezolid* is an antimycobacterial agent, developed at JHU, that has been
shown to have promising activity against both drug-susceptible and DR-TB.
Early studies indicate that addition of sutezolid to the standard TB
treatment regimen leads to significantly improved efficacy. Sutezolid could
represent a turning point in managing this global public health
crisis. Johns Hopkins University is in discussions with a company called
Sequella about exclusively licensing JHU’s secondary patents for this
potentially life-saving drug. A licensing agreement that does not include
necessary provisions to ensure timely development, affordability and
accessibility will have detrimental effects on the lives of TB patients
globally.


Interested in taking targeted action at JHU or on your campus? Email us at:
info at uaem.org

Thanks!
-- 
*Merith Basey MSc*
Executive Director
Universities Allied for Essential Medicines <http://uaem.org/>
merith at uaem.org
202-556-7319
@uaem @globalDiaBEATes



-- 
*Merith Basey MSc*
Executive Director
Universities Allied for Essential Medicines <http://uaem.org/>
merith at uaem.org
202-556-7319
@uaem @globalDiaBEATes



More information about the Ip-health mailing list